Home Overview Research Programs Shared Facilities News & Outreach Technology Transfer Employment About PHRI

 
 

For information on PHRI's Patents and Licensing Program, please contact:

Tatiana Litvin-Vechnyak, Ph.D.
Director of Biomedical and Life Sciences Licensing
Office of Research Commercialization
Rutgers University

Phone: (848) 932-4456
e-mail: litvinta@rutgers.edu




PHRI Patents and Patent Applications
 



Allele-discriminating primers
Antibiotic dosage
Antisense target selection
Bacteriocides
Beta-lactamase inhibitors
Binary probes
Caspofungin resistance probes
Coding distributed arrays
Coupled replication-translation
HIV-1 antibodies
HIV-1 vaccines
Isothiocyanate antibiotics
Luminescent sensors
Mevalonate kinase polypeptides and polynucleotides
Molecular beacons
Oligonucleotide arrays
Oligonucleotide-facilitated coalescence of cells and liposomes
Selection of improved ribozymes
Smart pins
Tuberculosis antigens
Yinyang probes




Allele-discriminating primers

Tyagi S, Kramer FR, and Vartikian R. US Patent 6,277,607 (August 21, 2001), US Patent 6,365,729 (April 2, 2002), and European Patent Application 00928752.5 (May 3, 2000). High specificity primers, amplification methods and kits.

Lizardi PM, Kramer FR, Tyagi S, Guerra CE, and Lomeli-Buyoli HM. US Patent 5,118,801 (June 2, 1992) and European Patent 043644 (April 17, 1996). Nucleic acid probes containing an improved molecular switch.

Lizardi PM, Kramer FR, Tyagi S, Guerra CE, Lomeli-Buyoli HM, Chu BC, Joyce GF, and Orgel LE. US Patent 5,312,728 (May 17, 1994) and European Patent 0436644 (April 17, 1996). Assays and kits incorporating nucleic acid probes containing an improved molecular switch.




Antibiotic dosage

Drlica K, Dong Y, and Zhao X. US Patent 6,265,181 (July 24, 2001) and US Patent 6,406,881 (July 18, 2002). Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection.




Antisense target selection

Drlica K and Wang J-Y. European Patent Application 02741991.0 (May 15, 2002). Selection of target sites for antisense attack of RNA.




Bacteriocides

Recsei P. US Patent 4,931,390 (June 5, 1990). Expression of the cloned lysostaphin gene.

Blackburn P, Gusik S-A, Polak J and Rubino SD. US Patent 4,980,163 (December 25, 1990). Novel bacteriocin compositions for use as enhanced broad range bacteriocides and methods of preventing and treating microbial infection.

Recsei P. US Patent 5,011,772 (April 30, 1991). High yield protein production system.

Blackburn P, Polak J, Gusik S-A and Rubino SD. US Patent 5,135,910 (August 4, 1992). Nisin compositions for use as enhanced, broad range bacteriocides.




Beta-lactamase inhibitors

Brown-Skrobot S, Novick RP and Projan SJ. US Patent 5,466,685 (November 14, 1995) and US Patent 5,633,245 (May 27, 1997). Inhibition of expression of beta-lactamase using esters of fatty acid alcohols.




Binary probes

Tyagi S, Kramer FR, Lizardi PM, Landegren UD, and Blok HJ. US Patent 5,759,773 (June 2, 1998) and European Patent 0688366 (May 22, 2002). Sensitive nucleic acid sandwich hybridization assays and kits.

Tyagi S. US Patent 5,807,674 (September 15, 1998) and European Patent 0682715 (April 5, 2006). Diagnostic assays and kits for RNA using RNA binary probes and a protein that is an RNA-directed RNA ligase.

Lizardi PM, Tyagi S, Landegren UD, Kramer FR, and Szostak JW. US Patent 5,652,107 (July 29, 1997). Diagnostic assays and kits for RNA using binary probes and a ribozyme ligase.




Caspofungin resistance probes

Perlin DS. PCT Patent Application PCT/US2006/029290 (July 26, 2006). Assays for resistance to echinocandin-class drugs.




Coded distributed arrays

Kramer FR, Tyagi S, Marras SAE, and Trunfio HE. US Patent Application 10/791,502 (March 2, 2004) and European Patent Application 04716455.3 (March 2, 2004). Optically decodable microcarriers, arrays and methods.




Coupled replication-translation

Wu Y, Ryabova LA, Kurnasov OV, Morosov IY, Ugarov VI, Volianik EV, Chetverin AB, Zhang D, Kramer FR, and Spirin AS. US Patent 5,556,769 (September 17, 1996). Coupled replication-translation methods and kits for protein synthesis.




HIV-1 antibodies

Tilley SA and Pinter A. US Patent 5,922,325 (July 13, 1999). Synergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the V3 loop and the CD4 binding site of gp120, and the use for immunotherapy of HIV-1 infection.

Pinter A and Kayman S. US Patent 5,643,756 (July 1, 1997) and US Patent 5,952,474 (September 14, 1999). Fusion glycoproteins.

Pinter A. US Patent 6,815,201 (November 9, 2004). HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies.




HIV-1 vaccines

Pinter A. US Provisional Patent Application 60/830,044 (July 10, 2006). HIV-1 peptides, nucleic acids, and compositions, and uses thereof.




Isothiocyanate antibiotics

Mustaev A and Kurepina N. US Provisional Patent Application 60/819,229 (July 6, 2006). Novel isothiocyanate compounds, pharmaceutical compositions and uses thereof.




Luminescent sensors

Mustaev A and Marras SAE. US Provisional Patent Application 60/822,235 (August 12, 2006). Dual sensitizer containing luminescent compounds, conjugates and uses thereof.




Mevalonate kinase polypeptides and polynucleotides

Wilding EI, Gwynn M and Iordanescu M-S. US Patent 6,306,633 (October 23, 2001). Polynucleotides encoding mevalonate kinase from Streptococcus pneumoniae.




Molecular beacons

Tyagi S, Kramer FR, and Lizardi PM. US Patent 5,925,517 (July 20, 1999) and US Patent 6,103,476 (August 15, 2000). Detectably labeled dual conformation oligonucleotide probes, assays and kits.

Tyagi S, Kramer FR, and Lizardi PM. European Patent Application 95904104.7 (November 14, 1994). Hybridization probes for nucleic acid detection, universal stems, methods and kits.

Tyagi S and Kramer FR. US Patent 6,150,097 (November 21, 2000) and European Patent Application 97923412.7 (April 14, 1997). Nucleic acid detection probes having non-FRET fluorescence quenching and kits and assays including such probes.

Kramer FR, Tyagi S, Alland D, Vet J, and Piatek A. US Patent 6,461,817 (October 8, 2002). Non-competitive co-amplification methods.

Tyagi S, Kramer FR, and Marras SAE. US Patent 6,037,130 (March 14, 2000). Wavelength-shifting probes and primers and their use in assays and kits.

Tyagi S, Kramer FR, and Alland D. European Patent 1230387 (August 16, 2006). Assays for short sequence variants.

Kramer FR. US Patent Application 10/426,556 (April 30, 2003) and European Patent Application 04751175.3 (April 29, 2004). Homogeneous multiplex screening assays and kits.




Oligonucleotide arrays

Chetverin AB and Kramer FR. US Patent 6,103,463 (August 15, 2000). Method of sorting a mixture of nucleic acid strands on a binary array.

Chetverin AB and Kramer FR. US Patent 6,322,971 (November 27, 2001), US Patent Applications 10/331,780 (December 31, 2002) and 11/088,979 (March 24, 2005), and European Patent Application 93906138.8 (February 19, 1993). Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids.




Oligonucleotide-facilitated coalescence of cells and liposomes

Kramer FR, Alsmadi OA, and Tyagi S. US Patent 7,129,087 (October 31, 2006) and European Patent Application 01987791.9 (October 11, 2001). Oligonucleotide-facilitated coalescence.




Selection of improved ribozymes

Kramer FR, Dubnau D, Drlica KA, and Pinter A. US Patent 5,616,459 (April 1, 1997) and European Patent 0600877 (January 26, 2000). Selection of ribozymes that efficiently cleave target RNA.




Smart pins

Chang TN and Tolias P. US Patent 7,097,810 (August 29, 2006) and European Patent Application 03762066.3 (June 26, 2003). Delivery of metered amounts of liquid materials.




Tuberculosis antigens

Gennaro ML, Lyashchenko KP, and Manca CMA. US Patent 6,087,163 (July 11, 2000) and US Patent 6,596,281 (July 22, 2003). Mycobacterium tuberculosis specific proteins and genes, mixtures of antigens and uses thereof.

Gennaro ML and Gomez MJ. US Patent Application 10/009,384 (August 20, 2002). Secreted proteins of Mycobacterium tuberculosis and their use as vaccines and diagnostic reagents.

Gennaro ML. US Patent Application 10/009,383 (March 4, 2002) and European Patent Application 00928851.5 (May 4, 2000). Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines.

Gennaro ML. US Patent Application 11/494,140 (July 26, 2006). Antibody profiles characteristic of tuberculosis state.




Yinyang probes

Li Q, Luan G, and Liang J. US Patent Application 10/398,832 (August 12, 2003) and European Patent Application 01977535.2 (October 5, 2001). Specific double-stranded probes for homogeneous detection of nucleic acid and their application methods.

 
     Copyright © 2017 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101